Daratumumab subcutaneous-based induction, consolidation and maintenance regimen reduced risk of progression or death by 58 percent compared to standard of care regimen1 First presentation of data from Phase 3 PERSEUS study highlighted in late-breaking abstract session at 2023 ASH Annual Meeting and simultaneously published in The New England Journal of Medicine1,2 BEERSE, BELGIUM, Dec.

与标准治疗方案相比，基于Daratumumab皮下诱导，巩固和维持方案的进展或死亡风险降低了58%[1]。第三阶段PERSEUS研究的数据首次发表在2023年ASH年会的后期摘要会议上，并同时发表在新英格兰医学杂志1,2 BEERSE，BELGIUM，12月。

12, 2023 (GLOBE NEWSWIRE) -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first data from the Phase 3 PERSEUS study highlighting significant clinical improvement with a DARZALEX® (daratumumab) subcutaneous (SC) formulation-based quadruplet induction, consolidation regimen and doublet maintenance regimen in the treatment of transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM).1 The data, showing significantly improved progression-free survival (PFS) in the Phase 3 study evaluating TE NDMM and clinically significant improvement in rates of overall complete response (CR) or better and minimal residual disease (MRD) negativity over the comparator arm,1 were featured as a late-breaking oral presentation at the 2023 American Society of Hematology (ASH) Annual Meeting (Abstract #LBA-1), taking place in San Diego, California from 9-12 December.

12023年（环球通讯社）--强生公司的杨森制药公司今天宣布了PERSEUS 3期研究的第一个数据，该研究强调了基于DARZALEX®（daratumumab）皮下（SC）制剂的四联体诱导的显着临床改善，巩固方案和双重维持方案治疗符合移植条件（TE）的新诊断多发性骨髓瘤（NDMM）。1数据，在评估TE NDMM的3期研究中显示无进展生存期（PFS）显着改善，并且与对照组相比，总体完全缓解率（CR）或更好和最小残留病（MRD）阴性率在临床上显着改善，在12月9日至12日于加利福尼亚州圣地亚哥举行的2023年美国血液学会（ASH）年会（摘要#LBA-1）上，1人被评为最新的口头演讲。

The data were published simultaneously in The New England Journal of Medicine.2 The PERSEUS study, conducted in collaboration with the European Myeloma Network, found that induction and consolidation treatment with daratumumab SC in combination with bortezomib, lenalidomide and dexamethasone (D-VRd), followed by daratumumab SC and lenalidomide (D-R) maintenance, reduced the risk of disease progression or death by 58 percent (Hazard Ratio [HR], 0.42; 95 percent Confidence Interval [CI] 0.30-0.59; P <0.0001), co.

这些数据同时发表在《新英格兰医学杂志》上。2与欧洲骨髓瘤网络合作进行的PERSEUS研究发现，达拉木单抗SC联合硼替佐米、来那度胺和地塞米松（D-VRd）进行诱导和巩固治疗，其次是达拉木单抗SC和来那度胺（D-R）维持治疗，将疾病进展或死亡的风险降低了58%（危险比[HR]，0.42；95%置信区间[CI]0.30-0.59；P＜0.0001）。